32.00
+3.23%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Surrozen
From its filings with the US Securities and Exchange Commission
Surrozen is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SRZN. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $3.5m and a net loss of $242.0m. At that date it held total assets of $98.7m and shareholders' equity of −$187.8m.
We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair. Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California.
Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pathway. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous limitations in harnessing the potential of Wnt biology in a tissue-selective manner. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling and form the foundation of our ophthalmology portfolio and research programs, which are designed to restore tissue structure and function in serious eye diseases with high unmet medical need.
Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt proteins, which are involved in activation and enhancement of the Wnt pathway. Wnt signaling is essential in tissue maintenance and regeneration throughout the body. Our current development efforts are focused on ophthalmology, where the biology of the Wnt pathway is clinically validated and localized delivery enables controlled therapeutic modulation.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Nov 2020
- Employees
- 44
- Website
- surrozen.com ↗
- Head office
- 171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. David WoodhouseIndependent Chairman of the Board$83,504
- Mr. Craig ParkerPresident, Chief Executive Officer, Director, since 2018$1.5m
- Mr. Charles WilliamsChief Financial Officer, Chief Operating Officer, Corporate Secretary$1.0m
- Dr. Yang LiExecutive Vice President - Research$847,193
- Dr. Anna BerkenblitIndependent Director$51,004
- Mr. Eric BjerkholtIndependent Director$53,504
- Mr. Christopher ChaiIndependent Director$65,004
- Dr. Mary Haak-FrendschoIndependent Director$56,004
- Dr. Tim KutzkeyIndependent Director$32,504
- Dr. Shao-Lee LinIndependent Director$51,004
- Dr. Mace RothenbergIndependent Director$50,004
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Surrozen Inc. employs 44 full-time employees in South San Francisco.
- The company's lead product candidates are multi-specific antibody-based therapeutics.
- Surrozen's SWAP and SWEETS technologies enable selective Wnt pathway modulation.
Weaknesses
- Surrozen's IPO was on 23 November 2020 with 74 employees.
- The company has only three product candidates: SZN-1326, SZN-043, and SZN-413.
- Surrozen's clinical stage status limits immediate revenue generation.
Opportunities
- Surrozen's Wnt pathway modulation technology targets tissue repair in multiple organs.
- The company's SWAP and SWEETS technologies could expand into new therapeutic areas.
- Surrozen's focus on Wnt pathway offers potential for multiple drug candidates.
Threats
- Surrozen's clinical stage development faces regulatory approval risks.
- The biotechnology sector has high competition for Wnt pathway therapies.
- Surrozen's limited employee count of 44 may hinder rapid development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.